The scavenger receptor (SR) super family consists of integral membrane glycoproteins that are involved in recognition of polyanionic structures of either endogenous (e.g., oxidized low-density lipoprotein) or exogenous (e.g., bacterial lipopolysaccharides) origin. SRs are structurally diverse and can be classifi ed into seven different classes (A -G) based on the multidomain structure of the individual members. SRs are present on various types of tissues, such as vascular, adipose, and steroidogenic tissues. In addition to modifi ed lipoprotein uptake, these proteins are also known to regulate apoptotic cell clearance, initiate signal transduction, and serve as pattern recognition receptors for pathogens. Different SRs are involved in many physiological and pathological processes; more importantly, the function of SRs is highly implicated in the initiation and progression of atherosclerotic plaque. Targeting the SR gene products that mediate the response to and uptake of modifi ed lipids holds great promise in the prevention of cardiovascular diseases. Inhibition of SR expression using a combined gene therapy and RNA interference strategy also appears to be an option for long-term therapy. The present review focuses on the involvement of SRs in atherosclerosis, thrombosis, and other cardiovascular diseases. Moreover, the role of SRs is not restricted to vascular lesions; it is also implicated in a number of different cellular functions.
Introduction
Scavenger receptors (SRs) comprise a structurally diverse group of membrane-bound proteins that are involved in cholesterol and lipoprotein metabolism. SRs were initially identifi ed as macrophage receptors based on their ability to recognize modifi ed lipoproteins (1) . Several classes of SRs (from A to G) have been identifi ed so far depending on the presence of shared structural domains; however, there is a great structural diversity among different classes ( Figure 1 ) (2) . SRs are present on different tissues including macrophages, monocytes, platelets, endothelial cells, smooth muscle, and epithelial cells. In addition to vascular tissues, they also have been detected in adipose and steroidogenic tissues (2) . SRs bind to a wide range of ligands including modifi ed high density lipoprotein (HDL), low density lipoprotein (LDL) particles, and other polyanionic ligands such as acetylated lowdensity lipoprotein (AcLDL), oxidized low-density lipoprotein (OxLDL), Gram-positive and Gram-negative bacteria, apoptotic cells, β -amyloid fi brils, and advanced glycation end products (AGE) ( Table 1 ) (3) . Because of its ability to bind diverse ligands and perform multiple functions, SRs have the potential to be involved in many physiological and pathological processes such as homeostasis, apoptotic cell clearance, and innate immunity. More importantly, these receptors have been highly implicated in atherosclerotic plaque initiation and progression as well (4) .
Targeting the SR gene products that mediate the response to and uptake of modifi ed lipids holds great promise in the prevention of cardiovascular diseases. The present review emphasizes the role of these receptors in atherosclerosis, thrombosis, and other cardiovascular complications.
Class-A SRs
Class-A SRs are trimeric transmembrane glycoproteins that are expressed primarily by macrophages and bind a variety of ligands, including modifi ed lipoproteins, bacterial products, and extracellular matrix proteins (Table 1) . Class-A SRs mediate ligand internalization as well as cell adhesion (5, 6) . Class-A SRs comprise at least four types of receptors: scavenger receptor A (SR-A), macrophage receptor with collagenous structure (MARCO), scavenger receptor with C-type lectin (SRCL), and scavenger receptor A-5 (SCARA5) (7 -9) .
SR-A are largely found on macrophages, but are also present on platelets, endothelial cells, and vascular smooth muscle cells. These receptors are postulated to be proatherogenic due to their ability to mediate uptake of OxLDL in macrophages and platelets (10, 11) . Initial studies of SR-Anull (Msr -/-) mice were performed in atherosclerosis-susceptible ApoE-defi cient (ApoE -/-) mice on a hybrid background (ICR/129) fed a chow diet; animals showed a 58 % decrease in aortic sinus atherosclerosis lesion area compared with ApoE -/-littermates (11) . The combined action of cluster differentiation 36 (CD36) (another class-B SR) and SR-A has been well demonstrated via a new mechanism in which platelet activation is stimulated by the combined action of CD36 and SR-A. The results showed that combined blockage of CD36 and SR-A completely shut down the p38 mitogen activated protein kinase (MAPK) phosphorylation induced by OxLDL, but had no effect on native LDL signaling activities. Activation of p38 MAPK by OxLDL enhanced the adhesion of platelets and blocking these two receptors signifi cantly reduced the adhesion of platelets to immobilized fi brinogen. Further study using murine platelets that were defi cient in either CD36 or SR-A shows that these two SRs are required for OxLDL signaling in platelets (12, 13) . Recently, M ä kinen et al. have studied the role of SR-A and CD36 in foam cell formation and atherogenesis by RNA interference (14) . They employed RNA interference (RNAi)-mediated silencing to downregulate the expression of these receptors. They found that decreased SR-A but not CD36 expression led to reduced foam cell formation caused by AcLDL in mouse macrophage, whereas the uptake of OxLDL was not altered. More importantly, silencing of SR-A upregulates CD36 and vice versa. In another set of experiment, when low density lipoprotein receptor (LDLR) -/-/ApoB 100/100 mice were kept on a Western diet, silencing of either SR-A or CD36 in bone marrow cells led to a marked decrease in lesion area, whereas simultaneous silencing of both receptors was not effective (14) .
MARCO is expressed largely on macrophages and to a lower extent on dendritic cells (15) . MARCO is implicated in host defense and pathogen clearance as binding to dead or apoptotic cells, bacteria, and lipopolysaccharides (LPS) elevates MARCO levels (16) . When challenged with Streptococcus pneumoniae , wild-type (WT) mice could clear the infection, whereas this ability was impaired in MARCO -/-mice, demonstrating the role of MARCO in the innate immune response against pathogens (17) . MARCO expression in human alveolar macrophages also plays a crucial role in the innate immunity against bacteria (18) . However, the roles of MARCO in binding modifi ed LDL and in atherogenesis have been less well studied.
In contrast to the other class-A gene products, SRCL is detected on endothelial cells but not macrophages and are thought to be involved in innate immune response against fungal infections (19, 20) . SCARA5 is also detected on epithelial cells but not macrophages and may play a unique role in the innate immune system and atherosclerosis (7) . In a study, it was found that catechin reduces atherosclerotic lesion 
Class-B SRs
Unlike the SR-A family, class-B SRs have multiple transmembrane domain receptors (Table 1) . Class B contains three members: CD36, scavenger receptor class B member 1 (SR-BI), lysosomal integral membrane protein II, and cluster differentiation 163 (CD163) (2) . Despite the high degree of homology between CD36 and SR-BI, these two receptors appear to play distinct roles in lipid metabolism and atherosclerosis.
CD36
CD36 is an 88 kDa membrane glycoprotein that was fi rst identifi ed on monocytes by monoclonal antibody OKM5 (22) . CD36 has an unusual structural organization, with two transmembrane domains, two very short intracytoplasmic domains, and a large heavily glycosylated extracellular domain. Both of the intracellular domains contain pairs of cysteines that are fatty acid acylated, thus presumably closely opposed to the inner leafl et of the cell membrane (23) . CD36 is present on many mammalian cell types, including platelets, erythroid precursors, and microvascular endothelium; most ' professional ' phagocytes (macrophages, dendritic cells, microglia, and retinal pigment epithelium); hepatocytes; adipocytes; cardiac and skeletal myocytes, epithelia of the gut, breasts, and kidneys (24) . The diverse group of ligands that bind to CD36 consists of oxidized phospholipids, thrombospondin-1, collagen, various microbial pathogens, apoptotic cells, fatty acids, and microbial diacylglycerides (24, 25) . CD36 affects very different cellular processes depending upon the nature of the ligand and the type and location of the cell that expresses it (26) .
The function of CD36 is complex and has been associated with diverse physiological processes (for instance, uptake of modifi ed lipid and apoptotic cells, long-chain fatty acid transport, adhesion, and angiogenesis), and its expression or deficiency has been linked with several pathological conditions, such as atherosclerosis, diabetes, infl ammation, and cardiomyopathy (24) . Studies of mice with targeted deletion of the CD36 gene have shown that loss of CD36 confers protection from diet-induced atherosclerosis; this limits infl ammation and tissue infarction associated with acute cerebrovascular occlusion, but may increase susceptibility to certain infections (27, 28) .
Further studies have confi rmed that the proatherogenic role of CD36 was highly likely to be mediated by the CD36 on macrophages, as transplantation of bone marrow from CD36-null mice into ApoE-null mice had the same effect on atherosclerosis as seen in the ApoE/CD36-double-null mice (27) .
On macrophages, CD36 plays an important role in foam cell formation. Incubation of CD36-defi cient monocytes/ macrophages with OxLDL resulted in a 40 % -60 % reduction in OxLDL binding and uptake compared to WT CD36-expressing cells. Macrophages isolated from CD36-null mice have a profound defect in OxLDL uptake and foam cell formation. Crossing the CD36-defi cient mice with a proatherogenic ApoE-null animal resulted in a signifi cant protection from lesion development. More importantly, animals fed with a Western diet showed a 70 % reduction in aortic lesion size and distribution (29, 30) .
Although much is known about the mechanism of OxLDL interactions with macrophages, only recent studies have demonstrated that CD36 also mediates platelet responses to OxLDL and contributes to the procoagulant state associated with hyperlipidemia and oxidative stress (31) . Podrez et al. demonstrated that CD36 might serve as a kind of primer or sensitizer for platelet activation leading to platelet hyperreactivity in response to various forms of OxLDL or specifi c oxidized choline glycerophospholipids (oxPC CD36 ) that are formed during LDL oxidation. In hyperlipidemic CD36
-/-/ ApoE -/-mice, the absence of CD36 signifi cantly protected these mice from the hyperlipidemia-related prothrombotic phenotype when compared to hyperlipidemic ApoE -/-without CD36 defi ciency (32) . In vitro , various forms of OxLDL and oxPC CD36 bind to human and mouse platelets in a CD36-dependent manner. Binding of these ligands to CD36 resulted in platelet activation, characterized by the increased integrin α IIb β 3 and P-selectin surface expressions (33) .
A signifi cant increase in the extent and rate of aggregation of platelets from hyperlipidemic ApoE -/-mice was compared to WT mice. This response was primarily blunted in platelets from ApoE -/-and CD36 -/-mice. No signifi cant differences were observed between platelets from WT and CD36 -/-mice on normal chow diet, thereby indicating that CD36 plays an important modulatory role in platelet function only in the setting of hyperlipidemia. Similar results were obtained when platelets from hyperlipidemic LDLR -/-mice were compared to platelets from LDLR -/-and CD36 -/-mice. Role of CD36 in thrombosis is restricted to the dyslipidemic milieu, where there is enhanced oxidative stress that can generate specifi c ligands for CD36 (33) .
Dawson et al. identifi ed CD36 on endothelial surface that mediates its antiangiogenic activity. CD36-mediated antiangiogenesis is triggered by its ability to activate a specifi c signaling cascade that results in diversion of a proangiogenic response to an apoptotic response (34) . Recently, Li et al. have shown that CD36 was abundantly expressed by murine arterial smooth muscle cells and the absence of CD36 attenuated reactive oxygen species (ROS) production in response to ferric chloride-induced vascular injury in a mouse carotid artery thrombosis model. These data suggest that CD36-mediated downregulation of antioxidant systems in vascular smooth muscle cells may contribute to its prothrombotic, proinfl ammatory, and proatherogenic effects (35) .
When CD36 binds to its ligands OxLDL and microparticles, it transmits a signal to the cell. In macrophages, this signal leads to OxLDL internalization and foam cell formation, whereas in platelets, it contributes to platelet activation and aggregation. It has been shown that these signals are relayed by a series of molecular interactions that involve specifi c tyrosine kinases from the Src family, serine/threonine kinases family, and MAPK family. The signal to the platelet is mediated by a MAPK called c-Jun N-terminal kinase (JNK). CD36 -/-mice had 16 % less phosphor JNK than those from WT mice. Inhibition of platelet JNK signifi cantly prolonged the time to thrombosis in mice transfused with WT platelets, but had no effect in mice transfused with CD36 -/-platelets. These data strongly suggested that CD36-mediated JNK signaling promotes platelet activation and thrombus formation in vivo (36) , thereby indicating that CD36 has both a proatherogenic and a prothrombotic role in the vascular system.
In addition to atherosclerosis, CD36 has also been implicated in promoting chronic infl ammation in Alzheimer ' s disease. Binding of β -amyloid fi brils with CD36 initiates infl ammatory signaling pathways leading to microglial activation, ROS production, and secretion of cytokines and chemokines. Interestingly, amyloid ligands, including β -amyloid and fi brillar apolipoproteins (C-II and A-I), have also been detected in human atheroma, and these ligands can initiate proinfl ammatory CD36 signaling that may drive infl ammation in the artery wall (37, 38) .
SR-BI
SR-BI, an 82 kDa membrane glycoprotein, contains a large extracellular domain and two transmembrane domains with a short cytoplasmic N-and C-terminal tail. SR-BI is expressed on the surface of macrophages, platelets, and steroidogenic tissues mainly in the adrenals, ovary, hepatocytes, and to some extent on endothelial cells (39) . Like CD36, it also binds to a variety of ligands including native lipoproteins, oxidized lipoproteins, AGE, and anionic phospholipids, and plays a pivotal role in cholesterol metabolism (40) .
The major physiological function of SR-BI is to mediate the selective transport of cellular uptake of lipids, especially cholesteryl esters from HDL and the bidirectional fl ux of unesterifi ed cholesterol between cells and lipoprotein (40) . Hepatic SR-BI regulates plasma lipoprotein metabolism, biliary cholesterol secretion, and the structure and composition of plasma HDL particles. Overexpression of SR-BI protein in mouse liver has been found to be associated with reduced levels of plasma HDL cholesterol, thus implicating a possible role for SR-BI in the transport of cholesterol from peripheral tissues to the liver (41) . Besides, there are a number of evidences where SR-BI and CD36 have been described.
In an earlier study, it has been demonstrated that oxPC CD36 bind specifi cally to SR-BI and that binding of oxPC CD36 prevents HDL association because of the close proximity of the binding sites for these two ligands on SR-BI. Moreover, oxPC CD36 has been recognized as a potent inhibitor of SR-BImediated uptake of cholesteryl esters in hepatocytes. Results obtained revealed that specifi c oxidized phospholipids that accumulated in vivo in oxidative stress may inhibit reverse cholesterol transport and contribute to the development of hypercholesterolemia and atherosclerosis (42) .
Furthermore, the expression of SR-BI in lipid-laden macrophages in human and murine atherosclerotic lesions (43) implicates that SR-BI might play an important role locally in the arterial wall. On the one hand, SR-BI expression by macrophage may protect against atherosclerosis by stimulating cholesterol effl ux and preventing foam cell formation. On the other hand, its function in the uptake of both modifi ed and native lipoproteins might enhance foam cell formation, thus rendering macrophage SR-BI a proatherogenic factor (44) . Zhang et al. demonstrated that inactivation of macrophage SR-BI promotes the development of atherosclerosis in ApoEdefi cient mice in the absence of changes in plasma lipids, HDL subpopulations, and cholesterol effl ux (45) .
Studies have also demonstrated that SR-BI in bone marrowderived cells facilitates the development of small fatty streak lesions in both LDLR -/-mice on Western type diet for only 4 weeks and in WT mice fed with a high-cholesterol diet. These data supported a unique dual role for SR-BI on bone marrowderived cells including macrophages in atherosclerotic lesion development (46) . Furthermore, binding of HDL to SR-BI on endothelial cells induces the production of nitric oxide (NO) by upregulating endothelial NO synthase (eNOS) expression through a kinase cascade and has a protective effect on hypercholesterolemia-induced vascular disease (47) .
Imachi et al. reported reduced levels of SR-BI on platelets from atherosclerotic disease patients that were inversely correlated with the intracellular cholesterol content of platelets and their ability to aggregate (48) . Disruption of SR-BI in mice resulted in a three-fold increase in free cholesterol levels in the circulation, resulting in an unusually high plasma unesterifi ed to total cholesterol ratio (UC/TC) (49) . Dole et al. described that the high UC/TC ratio observed in SR-BIdefi cient mice is associated with thrombocytopenia due to high platelet clearance rates, increased intracellular cholesterol content, and abnormal platelet morphologies (49) . Recently, Korporaal et al. found that disruption of SR-BI in mice resulted in active circulating platelets, increased adherence to immobilized fi brinogen, and increased susceptibility to arterial thrombosis in vivo . Hence, SR-BI is essential not only for HDL cholesterol homeostasis and atherosclerosis susceptibility, but also for maintaining normal platelet function and prevention of thrombosis (50) .
Furthermore, Ma et al. investigated the effect of SR-BI defi ciency on platelet aggregation and thrombosis. They found that SR-BI defi ciency alone, under normolipidemic conditions, does not lead to a major defect in platelet aggregation, while hyperlipidemic milieu associated with non-bone marrow-derived SR-BI defi ciency is the major cause of the thrombocytopenia and abnormal morphology (51) .
An earlier study by the same group has shown SR-BI as the platelet SR that mediates the antiplatelet activity of OxHDL. Interestingly, the antiplatelet effect of OxHDL/SR-BI communication was independent of the eNOS/protein kinase B pathway, known to play a role in HDL/SR-BI-induced eNOS activation in endothelial cells. These results were suggestive of a dual role played by SR-BI in platelet function and thrombosis. Studies using chimeric mice revealed that nonbone marrow-derived SR-BI defi ciency leads to platelet hyperreactivity and thrombocytopenia, and platelet-specifi c SR-BI is required for normal platelet responses (52) .
Although CD36 and SR-BI have been shown to bind OxLDL with similar high affi nity, the metabolism of OxLDL by these two class-B SRs has not been compared directly. However, in a study, it was found that CD36 and SR-BI differ in their ability to internalize and degrade OxLDL. Both class-B SRs might play an opposite role not only in the context of atherosclerosis, but also thrombosis; while CD36 promotes a prothrombotic phenotype, SR-BI might counteract thrombus formation by suppressing platelet activation (53) .
CD163
CD163 is found to be expressed on monocytes and macrophages, in both membrane-bound and soluble forms. It plays an important role in the regulation of anti-infl ammatory responses, pathogen recognition, and atheroprotection probably through elevation in expression of heme oxygenase and in removing free hemoglobin (54) . Patients with hematological, infl ammatory, and lysosomal storage diseases also have a high level of soluble CD163, and it may thus serve as a biomarker for such conditions (55) .
Class-D SRs
Class D is comprised of CD68 (Macrosialin) which are heavily glycosylated type I transmembrane proteins and expressed in macrophages (56) . Macrosialin levels are also observed to be increased by a proatherogenic diet. It has been identifi ed as a receptor for OxLDL (57) . Macrosialin receptor is expressed in macrophage foam cells in atherosclerotic plaques of ApoE -/-mice, but its role in atherogenesis is unknown (58) .
Class-E SRs
Class E comprises of just one member: the lectin-like OxLDL receptor 1 (LOX-1) ( Table 1) . It is a 50 kDa type II membrane glycoprotein which contains a short N-terminal cytoplasmic domain, a single transmembrane domain, and an OxLDLbinding C-terminal extracellular C-type lectin-like domain (59) . LOX-1 assembles on the cell surface in hexamer form or larger, comprising three homodimeric LOX-1 molecules bound to OxLDL. It is expressed on endothelial cells, macrophages, smooth muscle cells, and platelets. The ligands to which LOX-1 binds comprise of oxidized LDL, apoptotic cells, activated platelets, and bacteria, thereby signifying its implication in the pathogenesis of atherosclerotic lesions (60) . The contributory role of LOX-1 in atherogenesis is supported by several lines of evidence: (i) OxLDL via activation of LOX-1 induces endothelial dysfunction/apoptosis, a major change in vascular biology seen at the beginning of atherogenesis (61) ; (ii) LOX-1 expression is dynamically upregulated in pathological conditions such as diabetes, hypertension, and dyslipidemia (62) .
Macrophage LOX-1 depletion inhibits foam cell formation, suggesting a role in atherosclerotic plaque initiation and progression. Importantly, the incidence of atherosclerotic plaques is signifi cantly lowered in LOX-1-defi cient mice (63) .
In endothelial cells, ligand binding to LOX-1 SR stimulates ROS production and both MAPK and nuclear factor-κ B activation, leading to increased expression of different adhesion gene products. Such elevated expression in endothelium can enable monocyte infi ltration, ultimately leading to monocyte differentiation and foam cell formation (64) .
LOX-1 was identifi ed as a major binding protein for OxLDL on human platelets in addition to CD36. During platelet activation, fusion of α granule membranes with plasma membrane is followed by the translocation of LOX-1 toward the platelet surface. Earlier studies have demonstrated that blocking of LOX-1 retards the ADP-induced plateletactivation event, thus implicating its role in determining platelet physiology (65) . Unlike CD36, LOX-1 is expressed only on activated platelets. This indicates that the two receptors function in different phases of platelet function. LOX-1 might be predominantly involved in thrombus formation, but does not appear to play a role in circulating resting platelets. When exposed on the activated platelet surface, it cross-links activated platelets and thus may stabilize thrombi or promote hemostasis (66) .
Class-F SRs
Class F consists of the scavenger receptor expressed by endothelial cells I and II (SREC-I and SREC-II) which are type I transmembrane receptors containing N-terminal epidermal growth factor-like domains, a transmembrane domain, and a long cytoplasmic tail postulated to induce signal transduction (4) . These receptors are expressed on mammalian endothelial cells and macrophages. They bind modifi ed lipoproteins such as AcLDL and OxLDL (67) . Studies in SREC-I -/-macrophages demonstrated that this receptor accounts for only 6 % of total AcLDL degradation, suggesting that it plays a minor role in foam cell formation (68) .
Class-G SRs
The chemokine (C-X-C) ligand 16 is a class-G SR that binds to phosphatidylserine and oxidized lipoprotein (SR-PSOX). SR-PSOX is highly expressed on macrophages, smooth muscle cells, dendritic cells, kidney, and B and T cells with lower levels detected on the endothelium (69) . This receptor is expressed in human and mouse atherosclerotic lesions, where it is present on endothelium, smooth muscle, and macrophages (70, 71) . It is also involved in acute and adaptive experimental autoimmune encephalomyelitis, CD8
+ T cell recruitment during infl ammatory valvular heart disease, and bacterial phagocytosis (72) .
SRs as a potential therapeutic target
SRs have a proatherogenic and a prothrombotic role in the vascular system (Figure 2 ) . Ligands of SRs such as OxLDL, microparticles, and apoptotic cells are generated in vivo by oxidant stress, hyperlipidemia, infl ammation, and cancer (29) . The ability to understand and modulate these mechanisms may offer new treatment strategies for patients. Therefore, targeting some SRs and their signaling pathways could be a strategy in the treatment of cardiovascular diseases.
Siegel-Axel et al. demonstrated that platelet-induced foam cell generation from progenitor cells could be partially prevented by 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors and agonists of peroxisome proliferator activated receptor-α and -γ . Furthermore, they cloned and characterized an immune-adhesion molecule which resembles the SR CD68 and binds its ligand OxLDL with high affi nity. CD68-Fc was found to bind to lipid-rich human atherosclerotic plaque specimens. CD68-Fc was able to inhibit plateletmediated macrophage foam cell formation and specifi c functions, such as matrix metalloproteinase-9 activity in vitro . Thus, the inhibition of platelet-mediated foam cell formation may be a promising option to infl uence atherosclerotic plaque formation (73) .
Recently, in a study, Hildebrand et al. investigated whether introduction of cholesteryl ester transfer protein (CETP) can normalize HDL-C transport to the liver and reduce atherosclerosis in SR-BI knockout (SR-BIKO) mice. They found that CETP restores HDL-C levels in SR-BIKO mice, but it does not change the susceptibility to atherosclerosis and other typical characteristics that are associated with SR-BI disruption . This may indicate that the pathophysiology of SR-BI defi ciency is not a direct consequence of changes in the HDL pool (74) .
Gene therapy can modulate SR function in atherosclerosis. Ectopic expression of membrane-bound SRs using viral vectors can modify lipid profi les and reduce the incidence of atherosclerosis. Alternatively, expression of soluble SRs can also block plaque initiation and progression. Inhibition of SR expression using a combined gene therapy and RNA interference strategy also holds promise for long-term therapy. RNAi-mediated treatment strategies of a single SR in macrophage might provide new ways to protect arteries against atherogenesis (75) .
Although this review focuses on the role of SRs in arthrosclerosis, thrombosis, and other vascular diseases, nevertheless, the role of SRs is not restricted to vascular lesions; these receptors are also implicated in a number of different cellular functions.
Phagocytosis is mostly mediated by SRs. Phagocytic cells express a broad range of receptors that participate in recognition and engulfment of apoptotic and senescent cells, including CD36. CD36 recognizes pathogen-associated molecular patterns, including erythrocytes infected with Plasmodium falciparum (76) . Animal studies with mice, genetically engineered to lack functional CD36, confi rm that this SR participates in recognition and engulfment of apoptotic cells, senescence cells, or cell fragments (77) . In addition to modifi ed lipoprotein uptake, these proteins are now known to regulate apoptotic cell clearance, initiate signal transduction, and serve as a pattern recognition receptor for pathogens (78) . Further studies in rodents and humans suggest that CD36 fatty acid interactions may contribute to the pathogenesis of metabolic disorders, such as insulin resistance, obesity, and non-alcoholic hepatic steatosis (79) . A number of links have been established between SR-BI and many cardinal features of human cardiovascular disease, including hypercholesterolemia, atherosclerosis, occlusive fi brin-rich coronary artery lesions, ischemia, myocardial infarctions, and cardiac dysfunction (80) .
Therefore, SR function is associated with both healthy and pathophysiological processes, such as homeostasis, apoptotic cell clearance, diabetic necropathy, age-induced cardiomyopathy, antigen cross-presentation in Alzheimer ' s disease, and different cardiovascular diseases.
Highlights
SRs comprise a structurally diverse group of membranebound proteins. SR function is associated with both physiological and pathophysiological processes. These receptors are highly implicated in the initiation and progression of atherosclerosis, thrombosis, and other cardiovascular diseases. Inhibition of SR expression using a combined gene therapy and RNA interference strategy holds a promise for long-term therapy.
